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Abstract
Purpose To compare the embryo outcomes of in vitro
fertilization/intra-cytoplasmic sperm injection with a gon-
adotropin-releasing hormone (GnRH) antagonist protocol
with follicle stimulating hormone (FSH) and with human
menopausal gonadotropin (hMG).
Methods We performed a retrospective cohort study in
465 patients. Stimulation was started by daily FSH injec-
tion, and either FSH was continued (FSH alone group) or
hMG was administrated (FSH-hMG group) after adminis-
tration of a GnRH antagonist. Primary outcomes were the
embryo profile (number of retrieved, mature, and fertilized
eggs, and morphologically good embryos on day 3) and
endocrine profile. Secondary outcomes were the doses and
durations of gonadotropin. Data were stratified by the
patients’ age into two groups: \35 years and C35 years.
Results In patients aged \35 years, the number of
retrieved oocytes in the FSH alone group was significantly
increased than that in the FSH-hMG group (13.7 vs 9.2,
P = 0.04), while there was no difference at other age
groups. The FSH-hMG group required a significantly
greater amount of gonadotropins at any age (all ages,
P \ 0.001;\35 years, P = 0.013; C35 years, P \ 0.001).
Conclusions Exogenous FSH alone is probably sufficient
for follicular development and hMG may not improve the
embryo profile in a GnRH antagonist protocol across all
age.
Keywords Embryo profile  Endocrine profile  FSH 
GnRH Antagonist  hMG
Introduction
In controlled ovarian stimulation (COS) of assisted repro-
ductive technology (ART), FSH is essential but signifi-
cance of luteinizing hormone (LH) supplementation is
controversial. Recent meta-analyses have shown that
human menopausal gonadotropin (hMG) leads to higher
pregnancy rates than recombinant follicle stimulating
hormone (rFSH) in a long gonadotropin-releasing hormone
(GnRH) agonist protocol [1–3]. The GnRH antagonist
protocol is widely used, as well as the GnRH agonist
protocol for COS for in vitro fertilization (IVF) and intra-
cytoplasmic sperm injection (ICSI). However, whether
supplementation of LH is beneficial in this protocol is
unclear. A few randomized controlled trials (RCT) reported
that highly purified hMG (hp-hMG) and rFSH showed
similar outcomes, such as the pregnancy rate, the preg-
nancy loss rate, and the live birth rate [4, 5].
In contrast, the inhibitory effect of GnRH antagonists on
LH secretion and a lower pregnancy rate has been shown in
a dose-dependent manner (Ganirelix Dose-finding Study
Group, 1998 [6]). Endogenous LH levels may fall too low,
particularly in advanced reproductive age women, indi-
cating that the effect of LH supplementation in the GnRH
antagonist protocol in older women is debatable. Conse-
quently, the optimal ovarian stimulation protocol according
to age needs to be established.
In this study, we aimed to examine the IVF/ICSI outcome
in a GnRH antagonist protocol with FSH or hMG among all
ages, including older reproductive age. We conducted a
retrospective analysis on the embryo and endocrine profiles.
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A total of 465 patients, 45 years or below, who received
ovarian stimulation with a GnRH antagonist protocol in our
hospital between April 2008 and May 2012 were retro-
spectively analyzed.
Treatment regimen
On day 2 or 3 of the treatment cycle, ovarian stimulation
was started by daily injection of FSH (rFSH; Gonalef and
Follistim, or urinary FSH (uFSH); Gonapure and Fo-
lyrmon-P) at a dose of 150–300 IU per day. A daily dose
of 0.25 mg of a GnRH antagonist (GANIREST and
Cetrotide) was initiated when the mean diameter of the
lead follicle reached 14–15 mm on transvaginal ultrasound.
After administration of a GnRH antagonist, either rFSH/
uFSH was continued (FSH alone group) or hMG (HMG
Ferring and HMG TEIZO) was administrated (FSH-
hMG group). The 75 IU of hMG contains 75 IU FSH and
75 IU of LH activity. The dose of rFSH/uFSH and hMG
was individually adjusted based on the number and size of
follicles and the estradiol level. There were no specific
criteria for determining whether FSH or hMG was chosen.
When at least two follicles developed to a mean of 16 mm
or more in diameter, hCG injection (PREGNYL 5,000 or
10,000 IU) or GnRH agonist nasal spray (BUSERECUR
600 lg) was administered to trigger egg maturation.
Ultrasound-guided transvaginal egg retrieval was per-
formed 34–35 h later. IVF, ICSI, or a combination of both,
was performed according to the condition of the sperm.
Data were stratified by the patients’ age into two groups:
\35 years and C35 years. In the FSH alone group (313
patients), 49 patients were \35 years and 264 were
C35 years. In the FSH-hMG group (152 patients), 23
patients were \35 years and 129 were C35 years.
Trial end points
Primary outcomes were the number of retrieved oocytes,
mature oocytes, normally fertilized (2PN) eggs, and mor-
phologically good embryos on day 3 (D3 good-quality
embryos), and hormone levels. Secondary outcomes were
the amount of gonadotropin used and the duration of
treatment.
Statistical analysis
Data are expressed as the mean ± SD for continuous
variables. Normality of distribution of continuous variables
was assessed with the Kolmogorov–Smirnov test.
Differences between groups of normally distributed vari-
ables (hormone levels) were assessed with the Student’s
t test, while non-normally distributed variables were eval-
uated with a non-parametric test (Mann–Whitney test). A
P value \0.05 was considered significant.
This study was approved by the institutional review
board of our hospital.
Results
Baseline characteristics
Baseline characteristics of the study participants are shown
in Table 1. The patients’ characteristics were similar
between the FSH alone group and the FSH-hMG group in
each age group, as well as basal hormone levels and antral
follicle count.
Endocrine profile
In every age group (total, \35 years, C35 years), serum
estrogen, LH and progesterone levels on the day of trigger
administration were similar between the FSH alone group
and the FSH-hMG groups (Table 2).
Egg and embryo profile
In patients aged\35 years, the number of retrieved oocytes
in the FSH alone group was significantly increased than
that in the FSH-hMG group (13.7 ± 10.2 vs 9.2 ± 4.2,
P = 0.04). The number of mature oocytes, the number of
fertilized eggs, fertilization rate, and the number of D3
good-quality embryos were similar between the two
groups. No differences were observed between the FSH
alone group and the FSH-hMG group in patients aged
C35 years and in total group (Table 3).
Amount of gonadotropin
In patients of every age group, the amount of gonadotropin
after starting GnRH antagonists increased in the FSH-hMG
group compared with the FSH alone group. This resulted in
a significantly higher amount of total gonadotropin
administered in the FSH-hMG group though the amount of
gonadotropin before a GnRH antagonist using was not
different between the two groups. The duration of gona-
dotropin treatment was similar between the FSH alone and
the FSH-hMG groups across all age groups (Table 4).
Logistic regression analysis revealed no correlation
between hMG addition and the good embryo outcome,
such as nine or more retrieved oocytes (odds ratio
(OR):0.76, 95 % confidence interval (CI) 0.48–1.21) and
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Age (years) 32.5 ± 1.6 31.7 ± 1.9 NS 39.8 ± 2.8 39.7 ± 2.6 NS 38.9 ± 3.9 38.8 ± 4.0 NS
Gravida 0.5 ± 0.7 0.3 ± 0.6 NS 0.7 ± 1.1 0.7 ± 1.1 NS 0.7 ± 1.0 0.7 ± 1.0 NS
Para 0.1 ± 0.3 0.04 ± 0.2 NS 0.2 ± 0.4 0.2 ± 0.4 NS 0.2 ± 0.4 0.2 ± 0.4 NS
BMI (kg/m2) 21.0 ± 2.9 21.1 ± 3.0 NS 21.1 ± 2.4 21.4 ± 2.2 NS 21.1 ± 2.5 21.3 ± 2.4 NS
Basal FSH
(mIU/mL)
6.7 ± 2.0 7.8 ± 1.9 NS 9.0 ± 5.0 8.4 ± 2.6 NS 8.7 ± 4.8 8.3 ± 2.5 NS
D2/3 FSH
(mIU/mL)
7.2 ± 1.8 7.3 ± 1.8 NS 8.4 ± 2.7 8.2 ± 2.2 NS 8.3 ± 2.7 8.1 ± 2.2 NS
D2/3 LH
(mIU/mL)
6.6 ± 2.8 5.5 ± 3.3 NS 5.2 ± 2.0 5.0 ± 1.6 NS 5.5 ± 2.2 5.0 ± 1.9 NS
D2/3 E2 (pg/
mL)
44.5 ± 22.3 41.2 ± 14.7 NS 40.9 ± 18.9 40.6 ± 15.1 NS 41.2 ± 19.5 40.4 ± 14.9 NS
AMH (ng/
mL)
2.82 ± 2.51 2.79 ± 1.36 NS 2.81 ± 2.74 2.90 ± 2.38 NS 2.76 ± 2.70 3.03 ± 2.43 NS
AFC 11.2 ± 6.3 11.0 ± 4.6 NS 7.8 ± 5.1 7.7 ± 4.8 NS 8.3 ± 5.4 8.2 ± 5.2 NS
Values are expressed as mean ± SD. Each characteristic was similar between the FSH alone group and the FSH-hMG group at any age with
regard to their baseline profile
BMI body mass index, E2 estrogen, AMH anti-Mu¨llerian hormone, AFC antral follicle count
Table 2 Endocrine profile on the day of oocyte maturation trigger
Age \ 35 years Age C 35 years Total
FSH alone FSH-hMG P value FSH alone FSH-hMG P value FSH alone FSH-hMG P value
LH (IU/L) 2.9 ± 2.0 2.4 ± 1.6 NS 3.0 ± 2.1 3.1 ± 2.4 NS 2.9 ± 2.1 3.1 ± 2.2 NS
E2 (pg/mL) 1842 ± 814 2006 ± 1056 NS 1655 ± 892 1734 ± 929 NS 1670 ± 877 1766 ± 948 NS
P (ng/mL) 0.7 ± 0.3 0.7 ± 0.3 NS 0.6 ± 0.3 0.6 ± 0.5 NS 0.6 ± 0.3 0.7 ± 0.5 NS
The hormone levels were similar between the two groups in every age group
Values are expressed as mean ± SD. P \ 0.05 is considered as statistically significant
E2 estrogen, P progesterone
Table 3 Egg and embryo profile
Age \ 35 years Age C 35 years Total
FSH alone FSH-hMG P value FSH alone FSH-hMG P value FSH alone FSH-hMG P value
Retrieved oocytes 13.7 ± 10.2 9.2 ± 4.2 0.04 8.8 ± 5.6 8.4 ± 5.7 NS 9.6 ± 6.7 8.5 ± 5.5 NS
Mature oocytes 7.6 ± 7.0 5.1 ± 3.3 NS 5.3 ± 4.6 5.3 ± 5.0 NS 5.7 ± 5.1 5.3 ± 4.8 NS
Fertilized eggs 8.8 ± 8.9 6.2 ± 2.3 NS 5.5 ± 4.0 5.0 ± 3.6 NS 6.0 ± 5.1 5.1 ± 3.5 NS
Fertilization rate (%) 71.2 ± 25.0 76.0 ± 15.6 NS 73.2 ± 26.1 72.6 ± 25.3 NS 72.9 ± 25.8 73.3 ± 23.9 NS
D3 good -quality
embryos
5.1 ± 4.8 4.2 ± 2.1 NS 3.4 ± 2.8 3.0 ± 2.5 NS 3.6 ± 3.2 3.2 ± 2.5 NS
Table indicating the number of retrieved oocytes, the number of mature oocytes, the number of fertilized eggs, fertilization rate (%), and the
number of morphologically good embryos on day 3 (D3 good-quality embryos). The number of retrieved oocytes in patients aged\35 years was
significantly increased in the FSH alone group than in the FSH-hMG group. Values are expressed as mean ± SD. P \ 0.05 is considered as
statistically significant
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seven or more mature oocytes (OR: 0.75, 95 % CI
0.51–1.11).
Discussion
This retrospective study showed that administration of
hMG in the late follicular phase did not improve the
embryo outcome in the GnRH antagonist protocol regard-
less of age. In addition, our study showed that there were
no differences in serum LH, estrogen and progesterone
levels with or without hMG administration.
Previous studies comparing FSH and hMG/FSH ? rLH in
a GnRH antagonist protocol [4, 5, 7–11] are varied in terms of
the type of intended patients, the timing for hMG adminis-
tration, and the type of gonadotropins. Most studies analyzed
relatively young women with regard to reproductive age (i.e.,
women \40 years old with a mean age of 30–33 years).
However, currently, women’s age for ART treatment is
getting older. In fact, the mean age for ART exceeded
35 years old since 2011 in the United States, and more than
half of infertile women in United States and Europe are older
than 35 years [12, 13]. Therefore, studies need to be per-
formed in women 40 years or above although there are only a
few. Chung et al. [14] performed a retrospective study in 141
cases stratified by an age of \40 years and [40 years. In
addition, Ko¨nig et al. [15] conducted a randomized controlled
trial in 253 patients only aged [35 years on LH supple-
mentation. Our study was retrospective but included larger
numbers of patients (465 patients) with mean age 38.8 years
(29–45 years), which consisted of 72 patients (15 %) in
\35 years old and 393 patients (85 %) in C35 years old. No
difference in the embryo and endocrine profile between
continuance of rFSH/uFSH and administration of hMG was
observed (e.g. the number of retrieved oocytes in total age
group, 9.6 ± 6.7 vs 8.5 ± 5.5, N.S.), and it is consistent with
those two studies [14, 15].
Our study was designed to compare FSH and hMG in
the late follicular phase, whereas some studies started
hMG/rLH from the beginning of stimulation [4, 5, 11].
Despite of the timing of starting LH supplementation,
hMG/rLH did not improve the embryo profile and
increased the amounts of gonadotropins.
With regard to the type and dose of gonadotropin used,
the FSH alone group involved both rFSH and uFSH, and
hMG contained hp-hMG, not rLH or recombinant hCG.
Therefore, quantifying the precise biological activity of
gonadotropins was difficult. However, Requena [16]
reported that endocrine and follicular profiles were not
different between rFSH ? rLH and hp-hMG stimulation
and previous studies also compared hMG with uFSH [5,
11, 14, 16].
Regardless of these limitations of our study, this is the
largest and most practical trial, which included women
aged C35 years, and hMG was added after a GnRH
antagonist.
Furthermore, our evaluation focused on the embryo
profile. Most studies investigated the pregnancy or the
delivery rate, but those outcomes are affected with a lot of
factors, not only quality of embryo, but also number of
embryo transferred, local hormone levels, uterine recep-
tivity, and other maternal complications. On the other
hand, quality of oocytes and embryos is one of the most
relevant factors determining the success of IVF treatment.
Among several factors affecting quality of embryos, an
ovarian stimulation protocol is eligible and adjustable.
In conclusion, exogenous rFSH/uFSH alone is probably
sufficient in the GnRH antagonist protocol for optimal
ovarian stimulation to achieve morphologically good
embryos across all ages. Moreover, hMG was not benefi-
cial in advanced reproductive age and rFSH/uFSH
increased the number of retrieved eggs and subsequently
may lead to better embryos in younger normo-gonado-
tropic patients.
Table 4 Gonadotropin amount
Age \ 35 years Age C 35 years Total
FSH alone FSH-hMG P value FSH alone FSH-hMG P value FSH alone FSH-hMG P value
Before GnRH ant. (IU) 1001 ± 437 1105 ± 358 NS 1249 ± 441 1265 ± 370 NS 1220 ± 450 1251 ± 385 NS
Before GnRH ant. (days) 5.5 ± 1.4 6.0 ± 1.7 NS 5.5 ± 1.4 5.4 ± 1.2 NS 5.5 ± 1.4 5.5 ± 1.3 NS
After GnRH ant. (IU) 685 ± 267 933 ± 388 0.0062 801 ± 258 1007 ± 333 \0.001 792 ± 269 993 ± 336 \0.001
After GnRH ant. (days) 3.6 ± 0.9 3.8 ± 0.9 NS 3.6 ± 0.8 3.6 ± 0.8 NS 3.6 ± 0.9 3.6 ± 0.8 NS
Total (IU) 1686 ± 590 2038 ± 555 0.013 2050 ± 591 2272 ± 542 \0.001 2012 ± 614 2244 ± 555 \0.001
Total (days) 9.2 ± 1.4 9.8 ± 1.6 NS 9.1 ± 1.5 9.0 ± 1.3 NS 9.1 ± 1.5 9.1 ± 1.5 NS
The total amount of gonadotropin and that after starting GnRH antagonists increased in the FSH-hMG group compared with the FSH alone group
in every age group
Values are expressed as mean ± SD. P \ 0.05 is considered as statistically significant
GnRH ant., GnRH antagonist
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